398 related articles for article (PubMed ID: 15953731)
1. Bicistronic lentiviral vector corrects beta-hexosaminidase deficiency in transduced and cross-corrected human Sandhoff fibroblasts.
Arfi A; Bourgoin C; Basso L; Emiliani C; Tancini B; Chigorno V; Li YT; Orlacchio A; Poenaru L; Sonnino S; Caillaud C
Neurobiol Dis; 2005 Nov; 20(2):583-93. PubMed ID: 15953731
[TBL] [Abstract][Full Text] [Related]
2. Reversion of the biochemical defects in murine embryonic Sandhoff neurons using a bicistronic lentiviral vector encoding hexosaminidase alpha and beta.
Arfi A; Zisling R; Richard E; Batista L; Poenaru L; Futerman AH; Caillaud C
J Neurochem; 2006 Mar; 96(6):1572-9. PubMed ID: 16441513
[TBL] [Abstract][Full Text] [Related]
3. Induced secretion of beta-hexosaminidase by human brain endothelial cells: a novel approach in Sandhoff disease?
Batista L; Miller F; Clave C; Arfi A; Douillard-Guilloux G; Couraud PO; Caillaud C
Neurobiol Dis; 2010 Mar; 37(3):656-60. PubMed ID: 20005954
[TBL] [Abstract][Full Text] [Related]
4. Metabolic correction in microglia derived from Sandhoff disease model mice.
Tsuji D; Kuroki A; Ishibashi Y; Itakura T; Itoh K
J Neurochem; 2005 Sep; 94(6):1631-8. PubMed ID: 16092933
[TBL] [Abstract][Full Text] [Related]
5. beta-hexosaminidase lentiviral vectors: transfer into the CNS via systemic administration.
Kyrkanides S; Miller JH; Brouxhon SM; Olschowka JA; Federoff HJ
Brain Res Mol Brain Res; 2005 Feb; 133(2):286-98. PubMed ID: 15710246
[TBL] [Abstract][Full Text] [Related]
6. Widespread distribution of beta-hexosaminidase activity in the brain of a Sandhoff mouse model after coinjection of adenoviral vector and mannitol.
Bourgoin C; Emiliani C; Kremer EJ; Gelot A; Tancini B; Gravel RA; Drugan C; Orlacchio A; Poenaru L; Caillaud C
Gene Ther; 2003 Oct; 10(21):1841-9. PubMed ID: 12960974
[TBL] [Abstract][Full Text] [Related]
7. Specific induction of macrophage inflammatory protein 1-alpha in glial cells of Sandhoff disease model mice associated with accumulation of N-acetylhexosaminyl glycoconjugates.
Tsuji D; Kuroki A; Ishibashi Y; Itakura T; Kuwahara J; Yamanaka S; Itoh K
J Neurochem; 2005 Mar; 92(6):1497-507. PubMed ID: 15748167
[TBL] [Abstract][Full Text] [Related]
8. Inefficiency in GM2 ganglioside elimination by human lysosomal beta-hexosaminidase beta-subunit gene transfer to fibroblastic cell line derived from Sandhoff disease model mice.
Itakura T; Kuroki A; Ishibashi Y; Tsuji D; Kawashita E; Higashine Y; Sakuraba H; Yamanaka S; Itoh K
Biol Pharm Bull; 2006 Aug; 29(8):1564-9. PubMed ID: 16880605
[TBL] [Abstract][Full Text] [Related]
9. Restoration of hexosaminidase A activity in human Tay-Sachs fibroblasts via adenoviral vector-mediated gene transfer.
Akli S; Guidotti JE; Vigne E; Perricaudet M; Sandhoff K; Kahn A; Poenaru L
Gene Ther; 1996 Sep; 3(9):769-74. PubMed ID: 8875224
[TBL] [Abstract][Full Text] [Related]
10. [Recent advances in molecular genetics of GM2 gangliosidosis].
Wakamatsu N
Nihon Rinsho; 1995 Dec; 53(12):2988-93. PubMed ID: 8577047
[TBL] [Abstract][Full Text] [Related]
11. Promoters for the human beta-hexosaminidase genes, HEXA and HEXB.
Norflus F; Yamanaka S; Proia RL
DNA Cell Biol; 1996 Feb; 15(2):89-97. PubMed ID: 8634145
[TBL] [Abstract][Full Text] [Related]
12. Production of recombinant beta-hexosaminidase A, a potential enzyme for replacement therapy for Tay-Sachs and Sandhoff diseases, in the methylotrophic yeast Ogataea minuta.
Akeboshi H; Chiba Y; Kasahara Y; Takashiba M; Takaoka Y; Ohsawa M; Tajima Y; Kawashima I; Tsuji D; Itoh K; Sakuraba H; Jigami Y
Appl Environ Microbiol; 2007 Aug; 73(15):4805-12. PubMed ID: 17557860
[TBL] [Abstract][Full Text] [Related]
13. Mice lacking both subunits of lysosomal beta-hexosaminidase display gangliosidosis and mucopolysaccharidosis.
Sango K; McDonald MP; Crawley JN; Mack ML; Tifft CJ; Skop E; Starr CM; Hoffmann A; Sandhoff K; Suzuki K; Proia RL
Nat Genet; 1996 Nov; 14(3):348-52. PubMed ID: 8896570
[TBL] [Abstract][Full Text] [Related]
14. Retrovirus-mediated transfer and expression of beta-hexosaminidase alpha-chain cDNA in human fibroblasts from G(M2)-gangliosidosis B1 variant.
Teixeira CA; Sena-Esteves M; Lopes L; Sá Miranda MC; Ribeiro MG
Hum Gene Ther; 2001 Sep; 12(14):1771-83. PubMed ID: 11560770
[TBL] [Abstract][Full Text] [Related]
15. Identification of an active acidic residue in the catalytic site of beta-hexosaminidase.
Tse R; Vavougios G; Hou Y; Mahuran DJ
Biochemistry; 1996 Jun; 35(23):7599-607. PubMed ID: 8652542
[TBL] [Abstract][Full Text] [Related]
16. Novel bicistronic lentiviral vectors correct β-Hexosaminidase deficiency in neural and hematopoietic stem cells and progeny: implications for in vivo and ex vivo gene therapy of GM2 gangliosidosis.
Ornaghi F; Sala D; Tedeschi F; Maffia MC; Bazzucchi M; Morena F; Valsecchi M; Aureli M; Martino S; Gritti A
Neurobiol Dis; 2020 Feb; 134():104667. PubMed ID: 31682993
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic evaluation of GM2 gangliosidoses by ELISA using anti-GM2 ganglioside antibodies.
Tsuji D; Higashine Y; Matsuoka K; Sakuraba H; Itoh K
Clin Chim Acta; 2007 Mar; 378(1-2):38-41. PubMed ID: 17196574
[TBL] [Abstract][Full Text] [Related]
18. Structure and distribution of an Alu-type deletion mutation in Sandhoff disease.
Neote K; McInnes B; Mahuran DJ; Gravel RA
J Clin Invest; 1990 Nov; 86(5):1524-31. PubMed ID: 2147027
[TBL] [Abstract][Full Text] [Related]
19. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism.
Sango K; Yamanaka S; Hoffmann A; Okuda Y; Grinberg A; Westphal H; McDonald MP; Crawley JN; Sandhoff K; Suzuki K; Proia RL
Nat Genet; 1995 Oct; 11(2):170-6. PubMed ID: 7550345
[TBL] [Abstract][Full Text] [Related]
20. Molecular heterogeneity in the infantile and juvenile forms of Sandhoff disease (O-variant GM2 gangliosidosis).
O'Dowd BF; Klavins MH; Willard HF; Gravel R; Lowden JA; Mahuran DJ
J Biol Chem; 1986 Sep; 261(27):12680-5. PubMed ID: 3017984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
